the best stocks to invest in

13 Best & Worst Broker-Dealers: Q3 Earnings, 2017

5 Annuity Business Beauty Secrets

3 Economic Scenarios for Investors to Watch in Next 5 Years

All eyes will be on the Senate after the Thanksgiving break as the lawmakers will vote on—and likely pass—the Senate Finance Committee’s tax reform bill. The task “is prodigious and the timeline is fast,” says political watcher Andy Friedman in his latest white paper, released Nov. 20.

When Congress last reformed the tax code, “the legislative process took over two years. Now Congress is attempting the same feat in a little over one month,” Friedman of The Washington Update said.

As it stands now, the House has passed its version of the tax reform bill, with a Senate vote expected the week of Nov. 27.

Next steps? “Assuming Senate passage, a ‘conference committee’ comprised of leaders from the two bodies will iron out the many differences between the bills. The single bill that comes out of that committee will go back to the House and Senate again for passage,” then the final version will go to President Donald Trump for his signature.

the best stocks to invest in: Oceaneering International, Inc.(OII)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Friday, energy shares surged by 2.60 percent. Top gainers in the sector included Oceaneering International (NYSE: OII), Willbros Group Inc (NYSE: WG), and Cobalt International Energy, Inc. (NYSE: CIE).

  • [By Monica Gerson]

    Oceaneering International (NYSE: OII) is projected to post its quarterly earnings at $0.35 per share on revenue of $641.85 million.

    Tennant Company (NYSE: TNC) is estimated to report its quarterly earnings at $0.25 per share on revenue of $180.93 million.

the best stocks to invest in: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Nektar Therapeutics (NKTR) has soared 21% to $18.80 after positive results from a pain-killer trial.

    Tiffany (TIF) has gained 1.6% to $93.90 after getting upgraded to Outperform from Market Perform at William Blair.

  • [By Sean Williams]

    Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.

  • [By Todd Campbell]

    Nektar Therapeutics (NASDAQ:NKTR) is an intriguing commercial-stage biotech company that’s just reported positive late-stage trial results for its pain-busting drug NKTR-181. However, shares have jumped on the news, and the company’s market cap has swollen to more than $3 billion. Is there more running room left for its investors?

the best stocks to invest in: KLA-Tencor Corporation(KLAC)

Advisors’ Opinion:

  • [By Jim Cramer]

    After a year of stock price fluctuations, the net result is that KLAC’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

     

  • [By Jim Cramer]

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Semiconductors & Semiconductor Equipment industry. The net income increased by 45.2% when compared to the same quarter one year prior, rising from $72.23 million to $104.90 million.

     

  • [By Jim Cramer]

    The debt-to-equity ratio is very high at 10.70 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Despite the company’s weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 3.00, which shows the ability to cover short-term cash needs.

     

the best stocks to invest in: Petroleo Brasileiro S.A.- Petrobras(PBR)

Advisors’ Opinion:

  • [By Money Morning News Team]

    Petroleo Brasileira SA Petrobras (NYSE ADR: PBR) is Brazil’s largest oil company and it’s our seventh best oil stock of 2016. Petrobras is an oil and natural gas exploration and production firm. It is also an operator of oil tankers, pipelines, and terminals in South America and globally.

  • [By Chris Lange]

    And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results Tuesday. The consensus estimates call for a net loss of $0.05 per share, as well as $18.05 million in revenue. Shares ended the weekat $8.91. The consensus price target is $11.22, and the 52-week range is $4.98 to $12.56.

  • [By Chris Lange]

    Short interest at Petroleo Brasileiro S.A. (NYSE: PBR), or Petrobras, decreased to 42.63 million shares from the previous 43.53 million. The stock traded at $9.06 a share, in a 52-week range of $5.19 to $12.56. Unfortunately, Petrobras may be trading on an entirely different set of fundamentals and sentiment due to its ongoing woes in Brazil.

  • [By Paul Ausick]

    Credit rating agency Standard & Poor’s on Friday raised its corporate credit rating on Petroleo Brasileiro S.A. (NYSE: PBR), commonly known as Petrobras, one notch, from B+ to BB-. The rating change does not lift Petrobras out of the non-investment grade category, but it lowers the risk from “highly speculative” to “speculative.”

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Petroleo Brasileiro S.A.- Petrobras (NYSE: PBR): Free Stock Analysis Report
     
    Bill Barrett Corporation (NYSE: BBG): Free Stock Analysis Report
     
    Northern Oil and Gas, Inc. (AMEX:NOG): Free Stock Analysis Report
     
    Rice Midstream Partners LP (NYSE: RMP): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Chris Lange]

    And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results late Thursday. The consensus estimates call for a profit of $0.16 per share, as well as $23.81 billion in revenue. Shares ended the weekat $8.86. The consensus price target is $10.82, and the 52-week range is $7.61 to $12.56.

Leave a Reply

Your email address will not be published. Required fields are marked *